<h4>Background</h4>Eltrombopag, a nonpeptide thrombopoietin receptor agonist (TPO-RA), has been reported to be an effective therapy for chronic immune thrombocytopenia (ITP). Here, MPL is linked to autoimmune thrombocytopenic purpura.